Epigenetic silencing of Bcl-2, CEBPA and p14ARF by the AML1-ETO oncoprotein contributing to growth arrest and differentiation block in the U937 cell line

Oncology Reports

Volumn 30, Issue 1, 2013, Pages 185-192

  Zhuang, Wen Yue ^a,b   Cen, Jian Nong ^a   Zhao, Yun ^a   Chen, Zi Xing ^a  

^a SOOCHOW UNIVERSITY   (China)

^b BEIHUA UNIVERSITY   (China)

Author keywords

AML1 ETO fusion gene; Bcl 2; CCAAT enhancer binding protein ; Epigenetic alteration; p14ARF

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GENOMIC DNA; HISTONE H3; HISTONE H3 LYSINE 27; HISTONE H3 LYSINE 9; HISTONE H4; METHYL CPG BINDING PROTEIN 2; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN ETO; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ARTICLE; BCL 2 GENE; CEBPA GENE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME TRANSLOCATION 8; EPIGENETICS; GENE EXPRESSION; GENE FUNCTION; GENE SILENCING; GENETIC TRANSFECTION; GRANULOCYTE; HETEROCHROMATIN; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MOLECULAR CLONING; MYELOMONOCYTIC LEUKEMIA; P14ARF GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; REGULATOR GENE; TUMOR SUPPRESSOR GENE;

CCAAT-ENHANCER-BINDING PROTEINS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOMONOCYTIC, ACUTE; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P14ARF; U937 CELLS;

EID: 84878207918     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2459     Document Type: Article

References (37)

1. Chevallier N, Corcoran CM, Lennon C, et al: ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein. Blood 103: 1454-1463, 2004. (Pubitemid 38168662)
2. Rowley JD: Molecular genetics in acute leukemia. Leukemia 14: 513-517, 2000.
3. Maiques-Diaz A, Chou FS, Wunderlich M, et al: Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs. Leukemia 26: 1329-1337, 2012.
4. Klampfer L, Zhang J, Zelenetz AO, Uchida H and Nimer SD: The AML1/ETO fusion protein activates transcription of BCL-2. Proc Natl Acad Sci USA 93: 14059-14064, 1996. (Pubitemid 26424245)
5. Pabst T, Mueller BU, Harakawa N, et al: AML1-ETO down-regulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med 7: 444-451, 2001. (Pubitemid 32298547)
6. Linggi B, Muller-Tidow C, van de Locht L, et al: The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med 8: 743-750, 2002. (Pubitemid 34778729)
7. Kelly PN and Strasser A: The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ 18: 1414-1424, 2011.
8. Krug U, Ganser A and Koeffler HP: Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 21: 3475-3495, 2002. (Pubitemid 34587717)
9. Ho PA, Alonzo TA, Gerbing RB, et al: Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood 113: 6558-6566, 2009.
10. Zhang DE, Hetherington CJ, Meyers S, et al: CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol Cell Biol 16: 1231-1240, 1996.
11. Sherr CJ and Weber JD: The ARF/p53 pathway. Curr Opin Genet Dev 10: 94-99, 2000. (Pubitemid 30113711)
12. Kamijo T, Zindy F, Roussel MF, et al: Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649-659, 1997. (Pubitemid 27513656)
13. Kohzaki H, Ito K, Huang G, Wee HJ, Murakami Y and Ito Y: Block of granulocytic differentiation of 32Dcl3 cells by AML1/ETO(MTG8) but not by highly expressed Bcl-2. Oncogene 18: 4055-4062, 1999. (Pubitemid 29363912)
14. Shikami M, Miwa H, Nishii K, et al: Low BCL-2 expression in acute leukemia with t(8;21) chromosomal abnormality. Leukemia 13: 358-368, 1999. (Pubitemid 29108074)
15. Banker DE, Radich J, Becker A, et al: The t(8;21) translocation is not consistently associated with high Bcl-2 expression in de novo acute myeloid leukemias of adults. Clin Cancer Res 4: 3051-3062, 1998. (Pubitemid 29001481)
16. Burel SA, Harakawa N, Zhou L, Pabst T, Tenen DG and Zhang DE: Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol Cell Biol 21: 5577-5590, 2001. (Pubitemid 32702461)
17. Ruas M and Peters G: The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378: F115-F177, 1998. (Pubitemid 28530512)
18. ARF in hematological malignancies. Leukemia 13: 1760-1769, 1999.
19. Hiebert SW, Reed-Inderbitzin EF, Amann J, Irvin B, Durst K and Linggi B: The t(8;21) fusion protein contacts co-repressors and histone deacetylases to repress the transcription of the p14ARF tumor suppressor. Blood Cells Mol Dis 30: 177-183, 2003. (Pubitemid 36539361)
20. Lu Y, Xu YB, Yuan TT, et al: Inducible expression of AML1-ETO fusion protein endows leukemic cells with susceptibility to extrinsic and intrinsic apoptosis. Leukemia 20: 987-993, 2006. (Pubitemid 43797289)
21. Fazi F, Zardo G, Gelmetti V, et al: Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia. Blood 109: 4432-4440, 2007. (Pubitemid 46743413)
22. Eberharter A and Becker PB: Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep 3: 224-229, 2002. (Pubitemid 34269514)
23. Kouzarides T: Histone methylation in transcriptional control. Curr Opin Genet Dev 12: 198-209, 2002.
24. Jones PA and Baylin SB: The epigenomics of cancer. Cell 128: 683-692, 2007. (Pubitemid 46273572)
25. Sharma S, Kelly TK and Jones PA: Epigenetics in cancer. Carcinogenesis 31: 27-36, 2010.
26. Tada Y, Brena RM, Hackanson B, Morrison C, Otterson GA and Plass C: Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. J Natl Cancer Inst 98: 396-406, 2006.
27. Bennett KL, Hackanson B, Smith LT, et al: Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma. Cancer Res 67: 4657-4664, 2007. (Pubitemid 46910170)
28. Hackanson B, Bennett KL, Brena RM, et al: Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. Cancer Res 68: 3142-3151, 2008.
29. Wouters BJ, Jordà MA, Keeshan K, et al: Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood 110: 3706-3714, 2007. (Pubitemid 350159640)
30. Kiefer MC, Brauer MJ, Powers VC, et al: Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 374: 736-739, 1995.
31. Hanada M, Delia D, Aiello A, Stadtmauer E and Reed JC: bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 82: 1820-1828, 1993. (Pubitemid 23278773)
32. Friedrich MG, Weisenberger DJ, Cheng JC, et al: Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res 10: 7457-7465, 2004. (Pubitemid 39557507)
33. Esteller M, Tortola S, Toyota M, et al: Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 60: 129-133, 2000. (Pubitemid 30058742)
34. Benanti JA, Wang ML, Myers HE, Robinson KL, Grandori C and Galloway DA: Epigenetic down-regulation of ARF expression is a selection step in immortalization of human fibroblasts by c-Myc. Mol Cancer Res 5: 1181-1189, 2007. (Pubitemid 350137113)
35. Hollenbach PW, Nguyen AN, Brady H, et al: A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 5: e9001, 2010.
36. Buchi F, Spinelli E, Masala E, et al: Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine. Leuk Res 36: 607-618, 2012.
37. Zapotocky M, Mejstrikova E, Smetana K, Stary J, Trka J and Starkova J: Valproic acid triggers differentiation and apoptosis in AML1/ETO-positive leukemic cells specifically. Cancer Lett 319: 144-153, 2012.